The Supreme Court Decision That Could Change Product Liability Forever: Why Most People Are Only Talking About Roundup.
On June 25, 2026, the U.S. Supreme Court gave Bayer and Monsanto a big win in Monsanto Co. v. Durnell. The Court ruled that thousands of state lawsuits about Roundup’s cancer-warning label may be blocked by federal law. Most news stories focus on glyphosate, the main ingredient in Roundup, and what this means for people who sued Monsanto after getting non-Hodgkin’s lymphoma.
But buried in the majority opinion is something significant that could reach far beyond pesticides and the EPA: the Court named several other categories of products, including over-the-counter drugs, cosmetics, meat, poultry, eggs and packaged foods that could potentially be shielded from state lawsuits by the same legal principle, depending on how lower courts interpret the ruling.
Some lawmakers are fighting back against the decision. An amendment introduced in the House of Representatives this week could alter the regulations that the Supreme Court’s decision hinges on.
And yet the legal precedent the Court established and the proposals that challenge it could have far wider implications than Roundup.
The Case Background
John Durnell, from Missouri, used Roundup weed killer for about 20 years before being diagnosed with non-Hodgkin’s lymphoma, a type of blood cancer. He sued Monsanto in 2019, saying the company should have warned him about the cancer risk on the label. The jury agreed and awarded him more than $1 million.
The case centers on a federal law called FIFRA, short for the Federal Insecticide, Fungicide, and Rodenticide Act. Passed in 1947 and made stronger in the 1970s, FIFRA sets the rules for how pesticides are sold and labeled. Any pesticide sold in the U.S. must be registered with the Environmental Protection Agency (EPA). Manufacturers submit a label, and the EPA reviews and approves it. Once approved, that label is the official federal standard, and companies cannot change it without EPA approval.
Buried in FIFRA is a short but consequential provision known as a preemption clause. It says that states “shall not impose or continue in effect any requirements for labeling or packaging in addition to or different from those required” under federal law. In plain terms, once the EPA approves a pesticide label, no state can require anything more or different on that label. The legal question Durnell’s case posed to the Supreme Court was whether that prohibition extends beyond state legislatures and regulators to state court juries as well.
Monsanto argued it does because the EPA had reviewed and approved Roundup’s label many times over several decades without requiring a cancer warning. The company’s position was that a state jury verdict punishing Monsanto for following that approved label was, in effect, a state-imposed labeling requirement that went beyond what federal law required. Durnell’s lawyers argued the opposite: A common-law tort claim is not a “labeling requirement” in the regulatory sense, and that Congress never intended FIFRA’s preemption clause to shut the courthouse doors on injured consumers.
Durnell won at trial. The Missouri jury found Monsanto responsible and awarded him over $1 million. Missouri’s appeals court agreed with the verdict. Monsanto then asked the U.S. Supreme Court to review the case, and the Court agreed with the manufacturer.
The Supreme Court sided with Monsanto in a 7-2 decision. Justice Kavanaugh delivered the opinion, joined by justices from both sides of the political spectrum, including Sotomayor and Kagan. The Court said that once the EPA approves a product label, it becomes a binding federal rule. State lawsuits asking for a different label are, in the Court’s view, adding extra or different requirements from what federal law requires, which FIFRA’s preemption clause does not allow.
Justices Jackson and Gorsuch were the only dissenters. They argued that the majority misunderstood federal pesticide law, making it harder for people like Durnell to seek justice in court.
Why This Decision Matters Beyond Roundup
In the opinion, Justice Kavanaugh acknowledged that allowing Durnell’s claim to survive “would affect more than FIFRA”, with FIFRA being the federal pesticide law at issue. He then listed other federal statutes with virtually identical preemption language, signaling where companies could attempt to use this decision next.
The Court also compared this case to Riegel v. Medtronic, a 2008 Supreme Court case that stopped failure-to-warn lawsuits against medical device makers whose products had FDA approval. The majority said Riegel was “dispositive,” meaning it set the rule for this case. They reasoned that if FDA approval blocks state lawsuits for medical devices, EPA approval could do the same for pesticides.
This comparison is important and could serve as a model for other industries with federal label approval systems, where similar legal arguments may arise.
The Federal Laws the Court Mentioned
The majority opinion listed these federal laws as having “similar or identical” preemption rules to the one that blocked Durnell’s lawsuit. Here’s what each law covers and why it’s important.
Products Regulated by the USDA
Meat: Federal Meat Inspection Act (21 U.S.C. Section 678). The Federal Meat Inspection Act requires federal inspection of beef, pork, lamb and other meat products and mandates federal approval of their labels. The statute’s preemption clause bars states from imposing any marking, labeling, packaging or ingredient requirements “in addition to, or different than” those established under federal law for products prepared at federally inspected establishments. Under the Durnell framework, state tort claims that would require different or additional labeling on federally inspected meat products could face a preemption argument.
Poultry: Poultry Products Inspection Act (21 U.S.C. Section 467e). The Poultry Products Inspection Act uses nearly identical preemption language for chicken, turkey and other poultry products prepared at federally inspected facilities, barring state labeling or ingredient requirements “in addition to, or different than” federal standards. The same preemption structure that applies to meat products under Section 678 applies here.
Egg Products: Egg Products Inspection Act (21 U.S.C. Section 1052). The Egg Products Inspection Act covers processed egg products — the liquid, frozen, and dried eggs used widely in commercial food production — processed at federally inspected plants. The statute’s preemption clause bars state or local labeling, packaging or ingredient requirements “in addition to or different than” those established under federal law for products from such plants, following the same structure as the meat and poultry statutes.
Products Regulated by the FDA
Over-the-Counter Drugs: (21 U.S.C. Section 379r). The FDA regulates over-the-counter (OTC) drugs (Tylenol, Advil, Benadryl, NyQuil, antacids, cough medicines and thousands of others) through standardized “monograph” systems that dictate exactly what warnings must appear on labels. Manufacturers are required to use those labels and cannot deviate from them without FDA approval, similar to how Monsanto could not change its Roundup label without EPA approval.
In recent years, there has been a wave of lawsuits over OTC products contaminated with benzene, including aerosol sunscreens and antiperspirants from major brands. Plaintiffs in those cases argue consumers were never warned about the contamination risk. After Durnell, those companies could have a significantly stronger argument that their FDA-approved label decisions preempt state failure-to-warn claims. The OTC statute is actually stricter than the pesticide law: It bars state requirements that are “not identical with” federal requirements, which may be an even higher bar for plaintiffs to clear.
Cosmetics: 21 U.S.C. Section 379s. The FDA oversees labeling for makeup, skincare, fragrances, hair care products and personal hygiene items under a preemption clause that bars state requirements “not identical with” federal standards. Historically, the FDA did not require pre-market approval of cosmetic products or labels, which limited the practical reach of the preemption clause. However, that landscape is changing. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) significantly expanded the FDA’s authority over cosmetics, requiring facility registration, product safety substantiation and new reporting obligations. As the FDA develops formal regulations under MoCRA, there could be more federal requirements that conflict with state law claims, potentially strengthening preemption arguments under this statute going forward.
Packaged Food Labels: 21 U.S.C. Section 343-1. The Nutrition Labeling and Education Act preempts state requirements on nutrition content and health claims that are “not identical to” federal standards. Lawsuits claiming that “low fat” or “heart healthy” labels were misleading could face new hurdles if the FDA approved that language. There is, however, an important exception Congress built in: Safety warnings on food are explicitly carved out of this preemption. Lawsuits over heavy metals in baby food, for example, may be on firmer ground, for now.
Real Cases That Could Be Impacted
The implications of the Durnell case are not abstract. Across the country, thousands of active lawsuits rely on exactly the kind of state failure-to-warn claims the Court called into question. In each of the following cases, state courts represent either the primary or last remaining avenue for people who say they were harmed by products that federal regulators reviewed without requiring a warning. If Durnell gets interpreted broadly, each of these situations could look very different.
Paraquat and Parkinson’s Disease
The paraquat MDL, consolidated in the Southern District of Illinois under Judge Nancy Rosenstengel, includes more than 6,000 cases from farmworkers and agricultural workers who allege long-term paraquat exposure caused Parkinson’s disease. A settlement framework has been in place since 2025, a qualified settlement fund was approved in March 2026 and an April trial was canceled as negotiations progressed.
But those talks have been complicated by a preemption motion filed by Syngenta, the maker of paraquat, arguing that FIFRA blocks the state failure-to-warn claims. The court held the MDL in abeyance pending the Supreme Court’s decision in Durnell. That decision is now here, and it could shift leverage in Syngenta’s favor.
Beyond Paraquat: All EPA-Registered Pesticides Are Now Impacted
FIFRA governs every pesticide sold in the United States, including thousands of herbicides, insecticides, fungicides and other chemicals bearing EPA-approved labels. Durnell’s holding could apply to any plaintiff bringing a failure-to-warn claim against a manufacturer of any EPA-registered pesticide. As scientific research continues to identify associations between specific chemicals and serious health conditions, plaintiffs in such cases have traditionally relied on state tort law when the EPA has not required a label change. After Durnell, every one of those cases could face a preemption argument backed by direct Supreme Court authority.
Tylenol and Prenatal Acetaminophen: Lawsuits Over Autism and ADHD
Families sued acetaminophen manufacturers, including the makers of Tylenol, claiming prenatal use contributed to children developing autism or ADHD. The federal MDL in New York was dismissed in 2024 after a judge excluded plaintiffs’ expert witnesses. Cases have since been refiled in other state courts. Tylenol is an OTC drug regulated under 21 U.S.C. Section 379r, one of the statutes the Durnell majority named. How that statute’s preemption clause interacts with these state claims is a question defendants are expected to press.
Benzene Found in Sunscreen and Antiperspirants
After independent laboratory testing found benzene in dozens of aerosol sunscreens and antiperspirants, lawsuits followed against brands including Neutrogena and Banana Boat. Federal preemption has already been raised as a defense in some of this litigation. These products are regulated as OTC drugs under 21 U.S.C. Section 379r, the same statute Durnell cited, and the FDA never required a benzene contamination warning on any of them. How courts weigh Durnell against the existing statutory framework, including its exceptions, will be a significant question in cases like these going forward.
Ultra-Processed Foods and Type 2 Diabetes Lawsuits
In December 2024, an 18-year-old named Bryce Martinez sued eleven major food manufacturers, alleging that a childhood diet of ultra-processed foods caused his Type 2 diabetes and fatty liver disease. A federal judge dismissed the case in August 2025 for insufficient specificity, finding the complaint failed to connect particular products to his diagnoses. Then, in December 2025, San Francisco’s city attorney filed a separate municipal lawsuit against major ultra-processed food manufacturers, which remains active.
These cases sit against a backdrop of growing scientific concern about preservatives, synthetic dyes, emulsifiers and other additives in processed foods, many approved under standards that predate current research. The food labeling preemption statute 21 U.S.C. Section 343-1 includes a carve-out that Congress specifically wrote for safety warnings on food, which distinguishes this category from the pesticide context. How courts could interpret that distinction as this litigation develops is an open question.
Baby Formula and Necrotizing Enterocolitis (NEC)
Families allege that Abbott Laboratories, maker of Similac and Mead Johnson, maker of Enfamil, knew their cow’s milk-based formulas dramatically increase the risk of necrotizing enterocolitis (NEC) in premature infants and failed to warn parents or hospitals. In April 2026, a Chicago jury awarded $70 million to four families who filed cases against Abbott. More than 800 cases remain pending in the federal MDL in the Northern District of Illinois.
Abbott has argued preemption under the Infant Formula Act, which courts have so far rejected. The Infant Formula Act does not contain the same express preemption clause language Durnell relied on, so the ruling does not directly control these cases. What Durnell contributes to the broader environment these cases are litigated in will depend on how courts interpret its scope going forward.
Depo-Provera and Where Drug Preemption Stops
Thousands of plaintiffs allege that long-term use of Depo-Provera, manufactured by Pfizer, caused meningioma brain tumors. The FDA approved a meningioma warning for the drug in December 2025, after Pfizer first became aware of the risk in 2023.
Prescription drugs occupy a different legal landscape than pesticides. The federal law governing prescription drugs contains no express preemption clause for failure-to-warn claims, and the FDA’s Changes Being Effected process allows manufacturers to add safety warnings without prior FDA approval. Durnell does not overturn the current system. Whether defendants invoke previous rulings and how courts respond are questions that will be answered in the years ahead.
What This Decision Means for People Harmed by Products
If you or someone you love has been harmed by a consumer product and you are considering a lawsuit, or if you are already in litigation involving a federally regulated product, this decision could matter. It does not automatically shut the door on every case. The strength of a preemption defense depends on which product is involved, which agency reviewed the label, how thorough that review was and whether the company had any ability to add warnings on its own.
Justice Jackson flagged these questions in her dissent, and they could be the real battlegrounds in courtrooms across the country for years to come. Whether the agency’s review was rigorous enough to carry preemptive weight, and whether the manufacturer could have acted unilaterally to add a warning, are the questions that could determine whether individual cases survive preemption challenges after Durnell.
What Durnell could do is give companies in a wide range of industries a powerful new argument at the front door of the courthouse. And given that seven justices, including two of the Court’s liberal members, signed on to the majority opinion, lower courts nationwide are likely to take that argument seriously.
What is clear is that this decision strengthens federal preemption arguments across the board, giving any company whose product has passed through federal regulatory review a more powerful tool to challenge state failure-to-warn claims. How aggressively that argument is made, which statutes it attaches to, which agencies it reaches and how courts ultimately interpret and limit it remain to be seen.